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Abstract 
Background: A common aberration in cancer is the activation of germline-specific proteins. The DNA-binding pro-
teins among them could generate novel chromatin states, not found in normal cells. The germline-specific transcrip-
tion factor BORIS/CTCFL, a paralog of chromatin architecture protein CTCF, is often erroneously activated in cancers 
and rewires the epigenome for the germline-like transcription program. Another common feature of malignancies is 
the changed expression and epigenetic states of genomic repeats, which could alter the transcription of neighboring 
genes and cause somatic mutations upon transposition. The role of BORIS in transposable elements and other repeats 
has never been assessed.
Results: The investigation of BORIS and CTCF binding to DNA repeats in the K562 cancer cells dependent on BORIS 
for self-renewal by ChIP-chip and ChIP-seq revealed three classes of occupancy by these proteins: elements cohabited 
by BORIS and CTCF, CTCF-only bound, or BORIS-only bound. The CTCF-only enrichment is characteristic for evolu-
tionary old and inactive repeat classes, while BORIS and CTCF co-binding predominately occurs at uncharacterized 
tandem repeats. These repeats form staggered cluster binding sites, which are a prerequisite for CTCF and BORIS 
co-binding. At the same time, BORIS preferentially occupies a specific subset of the evolutionary young, transcribed, 
and mobile genomic repeat family, SVA. Unlike CTCF, BORIS prominently binds to the VNTR region of the SVA repeats 
in vivo. This suggests a role of BORIS in SVA expression regulation. RNA-seq analysis indicates that BORIS largely serves 
as a repressor of SVA expression, alongside DNA and histone methylation, with the exception of promoter capture by 
SVA.
Conclusions: Thus, BORIS directly binds to, and regulates SVA repeats, which are essentially movable CpG islands, via 
clusters of BORIS binding sites. This finding uncovers a new function of the global germline-specific transcriptional 
regulator BORIS in regulating and repressing the newest class of transposable elements that are actively transposed in 
human genome when activated. This function of BORIS in cancer cells is likely a reflection of its roles in the germline.
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Background
Transposable elements (TEs) play active roles in nor-
mal genome evolution in humans [1] and in primates 
in general [2], as well as in sporadic genome rearrange-
ment [3–5] including deleterious events associated with 
pathology [6–12]. Multiple polymorphisms and intron 
evolution in normal human populations are largely facili-
tated by TE insertions [13, 14]. A substantial and distinct 
role of satellite repeats was also recently demonstrated 
for double-strand breaks (DSBs) incidence upon replica-
tion stress [15]. Active families of TEs (L1, Alu, and SVA) 
account for a large number of germline mutations [16]. 
In cancer, insertions of mobile element and the recom-
bination between them have been identified as causes 
of many cancers [12, 17, 18], with some repeats shown 
to become aberrantly expressed [17, 19] to acquire a 
potential to change the regulation of neighboring genes 
[17, 20, 21] and to destabilize chromosomes [7, 22]. The 
effect of repeated DNA in the origins and progression of 
cancer and tumor cell physiology could be two-pronged: 
the induced change of expression in neighboring or tar-
geted genes [22–24] and the structural destabilization of 
the epigenetic landscape of chromosomes [2, 25]. These 
two effects are interrelated, as epigenetic changes in the 
repeats open chromosomal domains for both aberrant 
changes in gene expression and elevated somatic recom-
bination. Some elements were also shown to act as bona 
fide enhancers [26].
The presence of a strong epigenetic component in such 
repeats and TE-mediated genome regulation and insta-
bility is well established [20, 27–30]. In cancer cells, there 
is likely a higher epigenetic impact of TEs, compared to 
the norm [12], as promoters of expressed mobile ele-
ments become hypomethylated and their transcription 
elevated [22, 31, 32].
The array of epigenetic changes leading to repeat 
deregulation in cancer cannot be understood without 
molecular analysis of repeats’ chromatin. This brings to 
light the role of CTCF and its paralog CTCFL/BORIS 
in these processes. In addition to serving as a bona fide 
transcription factor, CTCF reads the epigenetic marks 
[33–36] and plays a key role in the formation of topologi-
cally associated domains (TADs) in chromatin [37–39], 
in remodeling chromatin structure [40], and in the for-
mation of chromatin boundaries [29, 41]. CTCF was also 
shown to have multiple binding sites embedded in TEs 
[42, 43]. CTCF target sites (CTSs) are also important for 
telomere repeat stability [44, 45]. Furthermore, the fact 
that CTCF control of gene expression and recombina-
tion requires physical contacts between different CTSs 
via looping [46–49] indicates that CTCF sites in repeats 
are not inert in the chromatin architecture, as indeed was 
demonstrated at some instances [50–53].
Taking into account the important role of CTCF in 
regulating TE expression and epigenetic maintenance, 
it is possible that the aberrant activation of its ger-
mline paralog CTCFL/BORIS in cancer has an impact 
on repeat physiology and genome stability. BORIS is a 
cancer testis (CT) gene [54], and its ectopic expression 
could be lethal or inhibitory for somatic cells because 
BORIS, being a germline transcription factor, activates 
gene expression of germline-specific genes on its own 
or in cooperation with CTCF [55]. Nevertheless, some 
cancer cells undergo adaptation/addiction to BORIS 
activation and incorporate the BORIS protein into their 
physiology [55, 56]. BORIS also interferes with a variety 
of other CTCF-specific functions in somatic cells, such as 
in the organization of chromatin loops that are alterna-
tive to the chromatin configuration of normal cells [55]. 
The ultimate molecular and physiological role of BORIS 
in cancer is still poorly understood, however, beyond 
the association with stemness [56], phenocopying of 
germline-specific gene expression pattern, and the corre-
sponding 3D chromatin organization [55]. In particular, 
it is not clear how some cancer cells became dependent 
on BORIS for their proliferation, making BORIS a poten-
tial anticancer target [57, 58].
While many genomic repeats are heavily methylated 
and BORIS has a probable role in DNA demethylation 
[57, 59–61], the role of BORIS in repeat biology has not 
been studied. Incidentally, even the most comprehensive 
genome-wide studies on CTCF tended to ignore the pos-
sible simultaneous presence of BORIS in cells studied, be 
it cancer or embryonic stem cells [48, 50, 62–64]. In this 
present study, we attempted to assess the specific pattern 
of BORIS recognition of genomic repeats in cancer cells 
and to link it to TE expression. As a result, we uncovered 
a surprising association of BORIS with one of the evo-
lutionary youngest families of actively transcribed and 
mobile repeats in human genome, the SVA family of TEs. 
Follow-up analysis of the modulation of BORIS expres-
sion revealed that it predominately acts as one of the 
mechanisms repressing the expression of these elements.
Results
BORIS expression in K562 forms a specific pattern of repeat 
binding
We have previously shown that tandem repeats (TRs) 
in a human cancer cell line may serve as foci for multi-
ple DNA damage events induced upon the resolution of 
mitotic chromosome bridges [65]. In that study, custom 
repeat microarray ChIP-chip was used to validate some 
of the enrichments identified in the preceding ChIP-seq 
analysis. The need for a two-method validation pro-
cedure stems from the fact that at present there is no 
unbiased way to align short next-generation sequencing 
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(NGS) reads to massively repeated DNA, while micro-
array analysis has well documented limitations of its 
own. Here, we employed a similar two-step approach in 
reverse; the repeats’ enrichment by DNA-binding pro-
teins was first assessed by ChIP-chip and then validated 
by ChIP-seq. We used mainly the established cancer cell 
line K562 as a model for the coexistence of CTCF and 
BORIS stably expressed at a relatively the same level, as 
assayed by RT-PCR [55], to assess genome repeat occu-
pancy by these two proteins. K562 retains a set of prop-
erties characteristic for cancer stem cells, e.g., the ability 
to initiate tumors in graft models, and the propensity to 
differentiate in response to exogenous stimuli [66]. As 
CTCF and BORIS have essentially the same composition 
of the DNA-binding domain, including the number of ZF 
and their spacing, as well as residues involved in DNA 
contacts (Fig. 1a), they show the virtually identical DNA-
binding specificity in vitro, albeit not in native chromatin 
[55]. Therefore, it was important to use a cell line where 
two proteins are expressed in equivalent amounts, such 
as K562. Unlike most established cancer cell lines or pri-
mary non-germline tumor cells, where the expression of 
BORIS is low, with only a minor subset of cells character-
ized by high BORIS expression [56], K562 expresses high 
level of BORIS largely localized to the nuclei (Fig.  1b). 
BORIS was also confirmed to be incorporated into tran-
scription regulation in K562 and to be required for its 
self-renewal [55].
For the initial analysis, by ChIP-chip, anti-CTCF and 
anti-BORIS immunoprecipitations were conducted and 
microarray hybridization was performed as described 
in Methods. The plot of normalized ChIP-chip fluores-
cence intensities showed indications of distinct binding 
patterns for BORIS and CTCF on highly enriched tiles 
(Fig. 1c). Significance analysis of microarray (SAM) indi-
cated that over 40,000 tiles were enriched differentially 
by CTCF and BORIS, but provided little clue about the 
occupancy of the rest of the repeats. The principal com-
ponent analysis (PCA) of arrays hybridized to CTCF and 
BORIS ChIP samples confirmed the presence of differ-
entially bound genomic repeats (Fig.  1d). The PCA also 
revealed the three expected scenarios of occupancy: 
binding by BORIS only, by CTCF only, and BORIS and 
CTCF co-binding being by far the largest group (Fig. 1e). 
As CTCF and BORIS have essentially the same DNA-
binding specificities in vitro, the differences in occupancy 
observed in vivo must be largely driven by the epigenetic 
factors.
Prior to proceeding further with analyses of repeat 
binding sequences, we conducted a validation of 
ChIP-chip data using an alternative high-throughput 
procedure, ChIP-seq, as conventional qPCR valida-
tion methods are not applicable or scalable to the TRs 
genome-wide. We set out to validate the three identi-
fied subsets: first, repeats preferentially enriched by 
CTCF (Fig.  1e), second, repeats preferentially enriched 
by BORIS (Fig.  1e), and, third, repeats equally enriched 
by both CTCF and BORIS (Fig. 1e, a subset of the mid-
dle group). Based on detailed PCA analysis, an additional 
cutoff across the three groups was applied to make uni-
form criteria for selecting the representative subsets for 
validation. For co-bound repeats we chose the 4× enrich-
ment for both proteins in all three ChIP-chip replicates, 
while for the Z5 groups we used 4× enrichment for one 
protein, with no enrichment for the other, also in all three 
replicates. Drawing the threshold at such a relatively high 
level also significantly reduced repeat redundancy in the 
TR dataset. For the ChIP-seq validation, we considered 
a ChIP-chip-positive repeat validated, if any tile from 
that repeat was reproducibly enriched at least twofold in 
ChIP-seq datasets with 95  % DNA match. Thus, all the 
repeats discussed below are repeats identified by ChIP-
chip and validated by ChIP-seq.
Co‑binding of BORIS and CTCF is characteristic for the 
simple tandem repeats
The simultaneous binding of BORIS and CTCF genome-
wide in cancer cell lines was shown to reset, at least par-
tially, the functions of CTSs in transcriptional regulation 
in accordance with germline-like program [55]. Thus, 
from the standpoint of cancer biology, it was important 
to characterize repeats bound by both CTCF and BORIS 
(CTCF and BORIS repeats, Additional file  1: Table S2), 
especially as they outnumbered other classes (Fig.  1e). 
The 171 distinct repeats in the CTCF and BORIS class 
were mostly represented by uncharacterized simple 
repeats, which can also be classified as VNTRs, and a 
small fraction of TEs, with the telomeric satellite TAR1 
notably dominating the rest of the group (Fig. 2a; Addi-
tional file 1: Table S2). It has to be appreciated that there 
is no certain way to determine whether both CTCF and 
BORIS co-bind the given individual repeat sequence, due 
to the multiple copies of repeats present and the pro-
pensity of CTCF and BORIS to induce interchromatin 
contacts [49, 55]. Nevertheless, the presence of cluster 
CTS is a strong indication of co-binding [55]. While this 
group included simple repeats long enough to harbor a 
single CTS, a more peculiar repeat type dominated this 
group. Namely, while a conventional 20-nucleotide GC-
rich signature sequence was readily derived for the group 
as a whole, consistent with the CTCF-binding motif 
generated for the whole genome (Fig.  2b, c), a longer 
consensus, which is more in line with the span of the 
actual CTCF binding [67], showed that a duplication of 
a shorter binding signature (denoted CTS′) is present in 
these repeats (Fig.  2d). Thus, while an individual repeat 
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Fig. 1 BORIS expression in K562 establishes a definitive pattern of repeat binding. a A schematic of CTCF and BORIS proteins with the four amino 
acids residues essential for DNA recognition by each zinc finger (ZFs) showing. The minor differences, indicated in yellow, do not affect the DNA-
binding specificity in vitro neither the consensus derived from the genome-wide binding study [55]. b LI-COR image of immunoblotting for BORIS 
and CTCF proteins in whole-cell protein extracts of K562 (BORIS positive) and HL60 (BORIS negative) cancer cell lines of myeloid origin. Below the 
immunofluorescent and DNA staining of the two corresponding cell lines. c The left panel shows the enrichment ratio (M) for CTCF and BORIS across 
all the tiles of the TR microarray. Dots represent microarray tiles enriched ≥4 by either CTCF (red) or BORIS (blue) with lines connecting different tiles 
belonging to the same repeat. SAM showed that 42,715 tiles were differentially occupied with FDR ranging from 0.103 to 0.245, with 0.75 correla-
tions between CTCF and BORIS arrays. Both measures indicate that a minority of the repeats were differentially bound by the two proteins. The right 
panel shows the linear fit of BORIS M ratios by CTCF M ratios, with the fit line and 95 % bivariate normal ellipse displayed. d Principal component 
analysis of ChIP-chip data from K562. PCA was performed with singular value decomposition (SVD), and the first principal component describing 
the trend of the data was excluded from the analysis. PC2 (42 %) explains the difference between CTCF and BORIS experiments, and PC3 (16 %) 
explains variance between the replicates. e Smoothed histogram for probe loading kernel density (Y axis) estimate for all probes along the PC2 axis. 
The mean is indicated, as well as the number of standard deviations from the mean (Z-score). Most probes show no significant loading on PC2, and 
no significant difference between CTCF and BORIS. Only a fraction of probes show a significant contribution to the PC2 axis
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unit does not enclose a bona fide cluster CTS, the tan-
dem arrangement of this class sets a potentially multiple/
staggered binding mode for CTCF and BORIS at these 
elements potentially generating a cluster site, if the tan-
dem structure is long enough (Fig.  2e). Therefore, we 
can hypothesize that co-binding of CTCF and BORIS 
to the same site, as in this group of repeats, is facilitated 
when two binding regions are juxtaposed in cis, as hap-
pens in the rest of the genome [55]. The fact that multiple 
uncharacterized simple repeats were found in this class 
indicates that these elements should have a regulatory 
function in the epigenome mediated by dual binding by 
CTCF and BORIS.
Analysis of CTCF and BORIS co-binding at repeated 
DNA would have been incomplete without assessing 
the least characterized region of human epigenome—
the chromatin of nucleolar organizer (NOR, or rDNA 
repeats). The bona fide human genomic rDNA has a very 
complex structure with multiple intervening sequences 
[68], and the NOR sequence from any human chromo-
some still remains to be determined. Therefore, human 
rDNA was not represented at TRF database and was 
not present on our microarrays. While we did not vali-
date rDNA binding by CTCF and BORIS in ChIP-chip, 
it is known that the repeat unit contains a strong hotspot 
for CTCF binding facilitating CTCF’s interaction with 
PolI transcription machinery [69]. We used a “consensus” 
human rDNA repeat, as in [65], to align ChIP-seq reads 
and assess the potential differences between CTCF and 
BORIS binding (Additional file 2: Figure S2B). Compar-
ing BORIS and CTCF binding showed that CTCF has 
a single binding site upstream of rDNA PolI promoter, 
consistent with published data in mice [70]. At the same 
time, BORIS appeared to have some enrichment at addi-
tional sites (Additional file  2: Figure S2A). These loca-
tions, however, corresponded to low-complexity regions 
(Additional file 3: Table S1), which were also present else-
where in the genome. Unlike the established CTCF bind-
ing site, the two selected BORIS sequences that appeared 
to be enriched in ChIP-seq were not confirmed to bind 
BORIS by EMSA in vitro (Additional file 2: Figure S2C). 
Thus, one may assume that such sites likely represent an 
Fig. 2 Distribution of repeat sequences and the co-binding consensus for BORIS and CTCFsites. a The chart showing the breakdown of repeat 
types among the features that are strongly bound (×4 enrichment or more) by both BORIS and CTCF, based on 171 ChIP-seq-validated repeats in 
Additional file 1: Table S2. b The co-binding DNA consensus derived from 171 co-bound repeats. c The whole-genome consensus for CTCF bind-
ing based on ChIP-seq data with the same parameters as in b. d The larger duplicate/staggered consensus for 171 repeats, when a 40-nucleotide 
window was interrogated. CTS’ denotes a short consensus for CTCF binding. e A model explaining the “staggered” emergence of cluster CTSs from 
tandem TRs containing CTS’
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artifact of short reads’ alignment to tandemly repeated 
DNA, and the additional such sites were not tested. The 
presence of BORIS at the main Pol I regulatory site in 
rDNA, however, indicates that BORIS might be involved 
in ribosome biogenesis in cancer cells by virtue of co-reg-
ulating the rDNA transcription with CTCF.
CTCF‑only enrichment is found in older repeat classes
The CTCF-only binding sites have a still unknown func-
tion in the genome, possibly unrelated to transcrip-
tion [55]. PCA results in Fig.  1e enabled us to separate 
the CTCF-bound repeats that were refractory to BORIS 
intrusion (Fig.  3a). Thirty-eight individual CTCF-only 
repeats in this group were validated by ChIP-seq (Addi-
tional file  2: Table S2). This set includes major known 
types of repeats with long evolutionary history, while 
evolutionary young and simple TRs were largely absent. 
This agrees well with the studies, indicating that some 
CTCF-only binding sites in repeats are conserved in 
evolution [67]. Two examples of ChIP-seq analysis for 
repeats in this class, a TR of two Alu elements (Fig. 3b) 
and a run of divergent centromeric alpha-satellites 
(Fig. 3c), showed a robust enrichment by CTCF as com-
pared to BORIS. As the enrichment of alpha-satellites by 
CTCF did not appear to be very strong, it is possible that 
a substantial fraction of alphoid elements in the K562 
genome are not occupied by CTCF. Combined with the 
fact that CTCF binding does not appear to be correlat-
ing with CENP-B box presence (Fig.  3c), this may even 
indicate that only non-centromeric alpha-satellites are 
bound by CTCF. The absence of strong BORIS binding to 
this group of repeats agrees well with the underrepresen-
tation of clustered CTS consensuses in this repeat group 
(not shown).
A movable and evolutionary youngest class of TEs is 
specifically enriched in BORIS binding
The BORIS-only repeats, where BORIS binds without 
the equivalent presence of CTCF, are the most revealing 
with respect to BORIS biology in cancer cells, as they are 
directly involved in the transcriptional regulation of the 
non-repeated part of the genome [55]. Remarkably, in 
this group, the only 10 TRF classes that were validated 
fell within a single repeat type: the SVA family (Fig.  4a; 
Additional file 1: Table S2). The SVA repeats are a hom-
inid-specific family, which is still currently mobile in the 
human genome owing to L1 activity [71, 72]. Overall, 
ChIP-seq analysis indicates that as much as 70 % of SVA 
elements could be occupied by BORIS in K562 (Fig. 4b). 
When this preference for SVA repeats was dissected for 
individual genomic repeat sequences, it became appar-
ent that the enrichment by BORIS peaked in the central 
part of the element composed of the GC-rich VNTRs 
(Fig. 4c–e). VNTRs in SVA are GC-rich sequences with 
unknown molecular function. The patterns of CTCF 
and BORIS occupancy at SVA elements were distinct 
(Fig.  4c), unlike in other elements analyzed in Fig.  3. 













































Fig. 3 Repeats preferentially bound by CTCF are comprised mostly 
of evolutionary older high-copy repeats. a A chart of repeat types 
from Additional file 1: Table S2 that are strongly bound by CTCF (×4 
enrichment or more by ChIP-chip) but are not enriched for BORIS (×1 
enrichment or less). b An example of the distribution of ChIP-seq tag 
enrichment for CTCF and BORIS at a tandem repeat of two differ-
ent Alu (shown in the schematic). The centers of normalized counts 
were binned along the DNA sequence (histogram bars) with the fit 
line applied accordingly. c An example of ChIP-seq tag enrichment 
distribution for BORIS and CTCF at an intrachromosomal run of ~10 
alpha-satellites (CENP-B box containing repeats are colored red). The 
histogram bars and smooth line—as in b
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VNTRs for BORIS binding in cancer cells. In order to 
exclude the possibility that SVA enrichment by BORIS is 
a specific property of K562, myeloid cells, or the female 
epigenome in general, we conducted ChIP-seq analy-
sis of an unrelated cancer cell line with aberrantly acti-
vated BORIS, Delta-47 cells [55]. Although the difference 
between BORIS and CTCF enrichment was not as dra-
matic as in K562, the preference of BORIS was evident 
(Additional file 4: Figure S1A), notwithstanding the lower 
level of BORIS in Delta-47 [55]. Considering that the 
SVA’s VNTRs are dynamic in number and composition 
themselves [73], the finding of a global regulator BORIS 
bound to a mobile and extremely variable repeat class 
could be indicative of an additional germline-specific 
function of BORIS.
In order to map the locations of BORIS binding sites 
in SVA elements with higher precision, we designed nine 
probes corresponding together to a full-size SVA-D ele-
ment (Fig. 5a) and analyzed them by EMSA with BORIS 
and CTCF proteins produced by in  vitro translation. 
EMSA assay showed that the weak binding found in the 






































































Fig. 4 SVA repeats are preferentially bound by BORIS with a strong preference for VNTR region. a The chart showing the dominance of SVA ele-
ments among the repeats from Additional file 1: Table S2 that are strongly bound by BORIS (×4 enrichment or more by ChIP-chip) with no enrich-
ment for CTCF (×1 or less). b BORIS occupancy is associated with SVAs repeats in K562 cells. The heatmap demonstrates the ChIP-seq enrichment 
of BORIS occupancy at SVAs element in K562 cells compared to input. The tag density was subjected to k-means ranked clustering with four clusters 
expected. c The ChIP-seq tag density distribution for a “canonical” full-length SVA-D element from Repbase shows that BORIS is clustered at the 
center of the element in a pattern complementary to CTCF. The normalized counts were binned along the DNA sequence (histogram bars) with 
the fit line applied accordingly. d The schematic structure of SVA-D element in e. e A diagonal alignment plot of DNA sequence for SVA-D in c, d 
indicating that BORIS enrichment corresponds to the VNTR region
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there (Fig.  5b). The central core of VNTR region, rep-
resented by two probes (5 and 6) in an EMSA, showed 
reproducible binding to both BORIS and CTCF proteins 
(Fig. 5b). Based on the EMSA data and CTCF motif anal-
ysis (Fig.  5b), these two VNTR sites juxtaposed to each 
other together form a cluster CTS, which is required for 
BORIS-only binding [55]. The 83-bp unique sequence 
embedded in the probe 6 in Fig.  5 was by itself unable 
to bind either protein (not shown). Not surprisingly, no 
discernible difference was detected between CTCF and 
BORIS in binding in vitro (Fig. 5b). This indicates that the 
BORIS’ preference for SVA binding observed in chroma-
tin (ChIP data) is likely determined by epigenetic factors. 
As CTCF is known to have both DNA methylation-sensi-
tive and methylation-insensitive binding sites, we verified 
whether BORIS is able to bind VNTRs when CpGs are 
methylated. EMSA analysis with methylated probes 
(Additional file  4: Figure S1B) showed that both CTCF 
and BORIS binding were abolished by full CpG methyla-
tion (Fig. 5b). This likely indicates that the preference of 
these sites for BORIS binding in chromatin, even if par-
tially controlled by DNA methylation, must be fine-tuned 
with respect to specific CpGs methylation.
What could be BORIS activity at SVA elements? Our 
previous results on the genome-wide consequences of 
modulation of BORIS expression indicated that BORIS 
could serve as an activator as well as repressor [55]. The 
distinct preference of the aberrantly expressed BORIS for 
SVA elements may potentially indicate that BORIS has 
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Fig. 5 BORIS binding to SVA elements in vitro is based on binding to sequences in the VNTR. a The design and positions of EMSA probes based on 
a test-case SVA-D element (hg19, chr11:107782497–107784211). The two CTCF-binding motif-matching sequences are shown in probe 5 (MEME p 
value 7.95e−06) and probe 6 (p value 1.32e−05). Red bars denote two unique sequences acquired by this retrotransposon. b EMSA shows that the 
tested SVA-D element contains at least two distinct BORIS and CTCF binding sites in the VNTR region, with binding sensitive to 5metC methylation 
in vitro. The binding in probe 3 was shown to be due to the presence of a unique sequence
Page 9 of 20Pugacheva et al. Epigenetics & Chromatin  (2016) 9:35 
and/or in cancer cells. As there is little doubt that SVAs 
mobilization is detrimental to genome stability, because 
they are under a strong repression in primates [73–76], 
a possible BORIS involvement in the regulation of SVA 
transcription must be biologically important. Indeed, 
the transcription is required for SVA transposition, and 
it could also have a regulatory role in the expression of 
neighboring genes.
BORIS acts as a transcriptional co‑repressor of a significant 
proportion of SVAs in K562 cells
While the transcription unit of SVAs is not well charac-
terized [76, 77], the Alu-derived sequences are the chief 
drivers of transposition in SVA [78]. Thus, SVAs contain 
sequences potentially transcribed by both RNA Pol III 
and Pol II, either of which can drive retrotransposition 
[79]. At the same time, based on structural considera-
tions, it is unlikely that SVA elements are actually tran-
scribed by Pol III [77]. We tested whether there was 
a difference in the occupancy of RNA Pol III factors at 
SVA elements between the publicly available ChIP-seq 
datasets for BORIS-positive K562 and BORIS-negative 
NHEK. Incidentally, we found no notable enrichment at 
any SVA elements for POLR3G, BDP1, BRF1, BRF2, or 
RPC155 (data not shown).
Next, we focused on the RNA Pol II transcription of 
SVAs and first took advantage of CAGE datasets available 
for K562 (BORIS positive) and NHEK (BORIS negative). 
The CAGE reads were aligned to the genome, and the 
extended areas corresponding to SVA elements were ana-
lyzed separately. However, the levels of SVA transcription 
were low, and SVA transcription in BORIS-positive K562 
cells was mostly well correlated with the BORIS-nega-
tive NHEK cells (Pearson correlation 0.98). At the same 
time, RNA-seq data available for human testis suggest 
that some SVA elements could be highly expressed; how-
ever, the two full-length (FL) SVA elements with highest 
expression in human testis showed no ChIP-seq enrich-
ment for BORIS at the VNTRs (Fig.  6a). The extension 
of analysis in Fig. 6a to 59 additional SVA elements with 
various degrees of BORIS occupancy showed only mar-
ginal levels of expression without any correlation with 
BORIS presence at the VNTRs (not shown). Thus, it is 
highly unlikely that BORIS bound to VNTRs serves as a 
transcription activator of SVA transcription in K562 cells.
At this point, one may hypothesize that the affin-
ity of BORIS to VNTRs of SVA elements demonstrated 
in K562 is a reflection of its role in germline pertaining 
to these elements and that this role is likely a repressive 
one. Indeed, we recently showed that despite BORIS 
previously perceived as an activator, BORIS upregula-
tion was linked to the repression of some genes and, 
vice versa, BORIS downregulation has resulted in some 
gene being activated [55]. Therefore, we investigated the 
K562 cells with downregulated BORIS. As SVA elements 
might be rapidly repressed by some other mechanism in 
the absence of BORIS, we could not rely on BORIS KO 
data [55], as the points of comparison there were sepa-
rated by a long period of time. Instead, we experimented 
with the downregulation of BORIS expression in K562 
cells for a short period of time using inducible shRNA. 
This approach enabled us to assess immediate down-
stream effects of BORIS downregulation. We constructed 
K562 cell lines with two alternative inducible anti-BORIS 
shRNA constructs stably integrated into the genome and 
conducted RNA-seq experiments after BORIS KD for 
48 h. Neither the degree of BORIS depletion nor the time 
span of the experiment was sufficient to induce the dif-
ferentiation, as was described for BORIS KO [55]. While 
genome-wide expression of genes responding to BORIS 
KD was almost evenly divided between up- and down-
regulation of transcription (data not shown), SVA ele-
ments longer than 1 kb were notably activated (Fig. 6d). 
In order to address whether any SVA were actually down-
regulated upon BORIS KD, we isolated the subclass of 
SVA elements that were already expressed in K562 and 
compared their expression to BORIS KD cells. As shown 
in Additional file 5: Figure S3A, the 70 SVA elements that 
were expressed did not significantly change their expres-
sion upon the downregulation of BORIS.
In order to understand better the nature of SVA acti-
vation, we treated control K562 cells with 5-AzadCyD 
(5-Aza-2′-deoxycytidine), an inhibitor of DNA meth-
ylation [27, 80–82], and DZNep (3-deazaneplanocin A), 
which indirectly suppresses EZH2 that catalyzes histone 
H3 lysine 27 methylation [83, 84]. Both drugs result in 
the removal of inhibitory epigenetic marks from DNA 
and chromatin, respectively. RNA-seq analysis of K562 
cells treated with these DNA methylation or H3K27me3 
inhibitors indicated that SVA elements that were already 
active were upregulated slightly (Additional file  5: Fig-
ure S3B, S3C), while the group as a whole was prefer-
entially activated. The 5-AzadCyD effect was similar to 
BORIS KD, and the DZNep effect was more pronounced 
(Fig. 6d). Thus, we next asked whether these treatments 
could be preferentially affecting the same subset of SVA 
elements as BORIS KD or a distinct one. Using the 
DZNep treatment as an example, Fig.  6e, f, we showed 
that BORIS KD largely acted concordantly with DZNep 
(correlation 0.77) to activate SVA transcription of the ele-
ments that were silent in the control. It was also evident 
that the BORIS KD-dependent activation was not spe-
cific to any particular subclass of SVA repeats (Fig.  6g), 
indicative of a common pathway.
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A distinct type of BORIS function at the SVA‑F1 TEs
The prevalent repressive role of BORIS on SVAs does 
not exclude the possibility that under certain conditions 
it could actually serve as an SVA activator. One such 
case could be the MAST2/SVA-F exon trap [85–87]. The 
capturing of MAST2 sequence by SVA-F resulted in the 
formation of a novel family (SVA-F1), represented by 81 
members in the hg19 human genome assembly [85, 88] 
The 5′ flanking region of SVA-F1 family is the result of a 
fusion between the first exon of MAST2, a gene expressed 
in testes, with the SVA-F repeat. Thus, it is conceivable 
that in testis BORIS acts as an activator of SVA-F1. This 
is possible as the binding of BORIS to SVA-A through 
SVA-F is within the VNTR region, but for SVA-F1 BORIS 
preferentially binds within the 5′ flanking region of the 
SVAs, upstream of the hexamer repeat region (Fig.  7a–
c). It is worth noting that the first exon of MAST2 is not 
just occupied by BORIS in K562 cells but is also aber-
rantly expressed in cancer cells together with BORIS 
expression (Additional file  6: Figure S4A). Thus, BORIS 
binding outside of SVA elements may serve as an exter-
nal promoter for SVA-F1 expression. The numbers of 
nucleotides captured from the MAST2 exon by SVA-F1 
vary from 36 to 382, with potentially four BORIS binding 
sites incorporated into 382 bp-promoter sequence (Addi-
tional file 6: Figure S4B). That may create a possibility for 
multiple TSSs starting from any of four BORIS binding 
sites. It may also explain the presence of MAST2 SVA-F1 
sequences of varying length. Indeed, the common feature 
of nearly all SVA-F1 transduced sequences is the pres-
ence of at least one BORIS binding site. In agreement 
with multiple BORIS binding sites in the transduced 
sequence the BORIS occupancy significantly correlates 
with the length of transduced sequence (Additional 
file 6: Figure S4B). While SVA-F1 sequences are strongly 
expressed in testis, they remain methylated in other 
instances of substantial hypomethylation of the genome 
[89]. Their expression is also quite low in BORIS-pos-
itive cell lines (Fig.  7d). Neither did the KO of BORIS 
in K562 cells change the overall expression of SVA-F1 
(Fig. 7e). Nevertheless, the ectopic BORIS expression in 
BORIS-negative cells appears to have a slight activating 
effect on SVA-F1 (Fig.  7f ). We also analyzed the puta-
tive promoter-trapping events similar to the MAST2 
case throughout human genome and identified several 
putative locations of such occurrences. For example, we 
found that NDUFV2, FDX1, PHKA1, WDR33, RHOT1, 
ZNF488, ZNF487, PHLPP2, TOM1L2, ARL4A, and 
MPPE1 promoters were trapped by SVA repeats and used 
for SVA expression in K562 cells (Additional file 7: Fig-
ure S5; Additional file 8: Table S3). One of the common 
features of all these promoters is the presence of BORIS 
binding sites inside the trapped sequences, occupied by 
BORIS in K562 cells and transcribed in BORIS-positive 
cells (Additional file 6: Figure S4; Additional file 7: Figure 
S5). Based on such data, one would be compelled to con-
clude that the capture of BORIS binding sites by SVAs is 
beneficial for their transcription. The trapping of BORIS 
binding sites within the promoter region of SVA repeats 
may also be indicative of an existing pathway for non-
random SVA integration.
In conclusion, it appears that BORIS acts as a co-
repressor of SVA transcription in K562 cells, alongside 
DNA methylation and heterochromatinization. It is 
therefore likely that BORIS plays a similar role in the ger-
mline, with the exception of promoter-trapping events. 
Fig. 6 Downregulation of BORIS and epigenetic remodeling show concordant activation of SVA transcription in K562 cells. a The two SVA elements 
with highest expression in testis with the position of BORIS ChIP-seq peaks in K562. The absence of strong BORIS binding indicates that BORIS 
is unlikely to act as SVA activator in testis. Genomic coordinates are in kb. The SVA-D shown is intergenic, while the SVA-B is antisense intronic. b 
RT-qPCR shows the downregulation of BORIS in K562 clones with stable integration of Tet-On inducible anti-BORIS shRNA constructs (site 1 and 
site 2), 48 h after shRNA induction. Un-infected K562 cells and a clone with the integrated empty vector were controls. Only the experiments in the 
presence of doxycycline (Dox+) are shown. c Immunoblotting with anti-BORIS mAbs demonstrates fourfold–fivefold depletion of BORIS protein in 
shRNA clones. The quantification of relative BORIS amount (white numbers) was performed using LiCor software and alpha-tubulin as a reference. 
d RNA-seq analysis of differential expression of 2223 SVA elements longer than 1 Kb mapped in the human genome versus K562 infected with the 
empty vector (SVAs that were constitutively silent were not included). Shown are the distributions of ratios of RNA-seq difference in: BORIS KD K562 
cells (paired two-tailed t test p value <0.001), K562 treated with 5-AzadCyD (5Aza) (paired two-tailed t test p value <0.001), and K562 treated with 
DZNep (paired two-tailed t test p value = 0.001). The RNA-seq reads enrichments for SVA elements were normalized to the total number of reads 
in each individual experiment. The mean and standard deviation diagrams are shown on top of each graph. The graphs demonstrate the overall 
increase in the shift toward higher SVA expression from BORIS KD to 5Aza and especially DZNep treatments. Vertical blue lines correspond to the 
unchanged expression over control, red—to twofold increase. e The RNA-seq analysis of BORIS KD, DZNep treatment, and the combination of both 
on the transcription of SVA elements that were apparently silent in control experiments (i.e., <10 normalized counts with over twofold increase by 
any treatment) shows a reproducible compound effect of BORIS KD and DZNep treatment on SVA activation (for the latter, the whole 2223 SVA 
sample’s paired two-tailed t test p value <0.001). The corresponding means of the distributions with standard errors of the mean: KD 1.03 ± 0.03, 
DZNep 1.37 ± 0.03, KD and DZNep 1.55 ± 0.02. f Dot-plot of RNA-seq normalized counts of BORIS KD versus DZNep treatment of K562, expressed 
as fold enrichment over the empty vector control. Only the SVA elements that were silent in the control are included. The blue lines correspond to 
cutoffs with no change in expression. g SVA elements that show concordant activation by BORIS KD and DZNep treatment do not belong to a pref-
erential SVA class. The pie diagrams show the breakdown of SVA classes among all 2223 elements included in the analysis and among 471 elements 
co-activated by both treatments




































































































































































Fig. 7 BORIS is enriched at the 5′-transduced sequence at the SVA-F1 family repeats. a A schematic of tested ~4 kb sequence encompassing SVAs 
elements. The sequences were used to plot the average tag density of BORIS ChIP-seq in K562 cells. b BORIS is predominantly associated with VNTR 
repeats of SVAs, with the exception of SVA-F1 where BORIS is bound at the 5′-transduced sequence. The average tag density (tags/ten million) is 
shown for BORIS versus the input of ChIP-Seq data in K562 cells. c The individual genomic examples of BORIS and CTCF occupancy corresponding 
to b. Data were normalized to the number of mapped reads and the number of SVA elements. d SVA-F1 expression is upregulated in testis. qRT-PCR 
data on total testis mRNA and two BORIS-positive cancer cell lines. e KD of BORIS in K562 does not change the SVA-F1 expression. qRT-PCR data of 
BORIS KD by shRNA relatively to the control empty vector (EV); SVA-F1 primers were from [88]. f The induced BORIS expression in MCF7 cells slightly 
upregulates SVA-F1 expression. qRT-PCR for two clones expressing ectopic BORIS [55] is compared to MCF7 transfected with the vector only (EV)
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These findings indicate a potential biological role of 
BORIS as a regulator of active TEs in human genome.
Discussion
The “explosive” chromosome instability is confirmed to be 
one of the defining features of cancer genome [90, 91]. This 
notion has sparked multiple attempts to find either a unify-
ing mechanism or a set of concurrent mechanisms for this 
process [92, 93]. The early onset of chromosome instability 
in cancer and pre-cancer cells strongly indicates the epige-
netic roots of the destabilization. In this context, the roles 
of chromatin states of genomic repeats in cancer are of sig-
nificant interest because they directly bridge the epigenetic 
landscape with a potential to destabilize genome via trans-
position and/or recombination. TEs that can pose a danger 
to genome integrity tend to be silenced for recombination 
and retrotransposition by epigenetic mechanisms [17, 73, 
94]. Here, we found evidence of BORIS involvement in the 
co-regulation of TEs. The established role of BORIS as a 
transcriptional regulator in cancer [55, 95] and as activator 
of testis-specific genes [70, 96, 97] might also be applicable 
to the states of genomic repeats in cancer cells. Neverthe-
less, the role of BORIS with respect to genomic repeats 
was previously totally unknown, despite the significant 
recent progress in understanding the transposition as the 
primary venue of genome evolution pertaining to the dis-
tribution of CTCF binding sites [67].
In this study, we established that BORIS, upon its acti-
vation at a relatively high level in cancer cells, has a sub-
stantial capacity to occupy the same sites in the repeated 
elements as CTCF (Fig. 1e). We can presume, with a high 
level of certainty, that it is a manifestation of the BORIS’ 
co-functions with CTCF in the normal germline [55, 70]. 
While co-binding is generally expected due to the DNA-
binding properties of the two proteins in vitro, the recent 
discovery of cluster sites being a prerequisite for CTCF 
and BORIS co-binding or binding of BORIS alone [55] 
suggests that a significant fraction of such repeats have 
cluster site configuration. Indeed, the assessment of 
DNA consensus characteristic for BORIS and CTCF co-
bound repeat sites (Fig. 2c) showed no significant devia-
tion from the basic unit of CTCF consensus derived from 
the genome-wide binding studies (Fig. 2b), but revealed 
the presence of a staggered arrangement (Fig. 2d), which 
potentially enables such TR locations to become super-
cluster sites with ample co-binding capacity. The char-
acterization of repeats that are co-occupied by CTCF 
and BORIS showed that the bulk of co-binding seems 
to be associated with the low-copy simple TRs (Fig. 2a). 
These elements have a relatively narrow length distribu-
tion, most are longer that 50 nt, indicating that they are 
under selection, possibly by the requirement to bind 
CTCF or BORIS. While expansion of short TRs is known 
to cause disease in a number of studied cases [98, 99], 
their genome-wide biological role is obscure. Thus, it is 
likely that BORIS and CTCF co-binding there uncovered 
a putative regulatory role for these elements in germline 
and/or cancer transcription.
The few repeat types that show a significant bias toward 
CTCF-only binding are rather enigmatic, as the function 
of CTCF-only sites genome wide is not well character-
ized [55]. The most notable case here is the centromeric 
repeats, where recombination is highly undesirable [100], 
but the transcription was nevertheless found to be of 
paramount importance for normal kinetochore forma-
tion [101]. While CTCF’s binding at alpha-satellites and 
its involvement in centromeric transcription were not 
studied, the interaction between CTCF and some centro-
meric proteins has been invoked at ectopic sites [102].
The most distinctive result generated by this study is the 
high preference of SVA repeats for BORIS binding, as com-
pared to binding by CTCF in K562 (Fig. 4). Unfortunately, 
in the absence of ChIP data for BORIS from human testis 
one cannot be absolutely sure that it is also the situation 
in normal testis. The functions for SVA that are described 
so far are attributed to the disruption/features of insertion 
sites rather than to the transcription originating within the 
insertion [103, 104]; yet the finding of BORIS binding hints 
at the regulatory role of SVA VNTRs themselves. The 
presence of several BORIS binding sites within the VNTR 
repeats (Figs. 4c, f, 5), which are actually required for SVA 
transposition [78], indicates that the BORIS protein and 
SVA elements may have even undergone co-evolution, 
as has been recently suggested for other ZF proteins [73]. 
Thus, one may expect the SVA elements to play a nota-
ble regulatory role in germline development and genome 
evolution in primates. In that regard, the recent studies on 
gibbon genome [2, 105] provided some invaluable insight 
into the new level of plasticity that SVA-like elements 
LAVA infused into primate genomes. At present, one can-
not conclude whether SVA TEs merely represent a genetic 
load or actually have a physiological role in germline. 
Despite human SVAs being associated with at least some 
chromosomal breaks [106], we could probably exclude 
the direct contribution of SVA elements into the meiotic 
recombination, as DSB maps of human meiosis [107] did 
not correspond to SVA locations (not shown).
By applying RNA-seq analyses to the K562 cells, we 
found a strong evidence of a substantial fraction of SVA 
elements being transcriptionally activated upon BORIS 
KD (Fig. 6d–f). This was a strong indication that BORIS 
acted as a repressor of SVA transcription for that repeat 
group. This conclusion is further reinforced by the find-
ing that this repressive activity is additive with DNA 
methylation and with the formation of repressive chro-
matin structure (Fig. 6e, f ). Therefore, we could conclude 
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that BORIS participates in the repression of SVA ele-
ments that are located in the heterochromatin-like 
regions of epigenome. This BORIS-mediated tier of SVA 
repression could have an exceptional significance in male 
germline, where the rounds of DNA demethylation [108] 
could potentially open SVA retrotransposons for a tran-
sient activation leading to germline mutations, as it has 
been found in pluripotent cells [109].
The addition of BORIS to cancer cells’ chromatin con-
stitutes a potent epimutation, as it could introduce a sub-
stantial change into CTCF’s functions [36]. Some of these 
changes were recently documented, particularly with 
respect of recapitulating the germline pattern of gene 
regulation [55]. With respect to the genomic repeats, the 
associated rewiring of epigenetic regulatory network, 
which is normally embodied by CTCF alone in somatic 
cells, may greatly alter the functional role of inserted 
repeats themselves, e.g., their expression and transposi-
tion, as well as their propensity to regulate neighboring 
genes and chromatin domains.
Conclusions
As a result of this study, by employing ChIP-chip and 
ChIP-seq approaches, we characterized CTCF and BORIS 
binding patterns of genomic repeat binding upon aberrant 
BORIS expression in the K562 cancer cell line, which is 
dependent on BORIS for proliferation. This study showed 
that, while CTCF-only enrichment is found in most 
known repeat classes, BORIS and CTCF bind together 
predominately to the uncharacterized simple TRs, which 
likely form compound cluster binding sites. We discov-
ered that the SVA elements, a presently active family of 
TEs in human genome with a strong mutagenic poten-
tial and a role in transcription regulation, are specifically 
enriched in BORIS, with binding concentrated at the 
VNTR region. Furthermore, RNA-seq analysis of BORIS 
KD in K562 showed that BORIS acts to repress multiple 
SVA, alongside the transcriptionally repressive histone 
modification and DNA methylation. These finding uncov-
ered a novel function of BORIS in controlling the levels of 
TE transcription in cancer cells and likely in the germline.
Methods
Cell culture, transfection, and lentiviral infection
K562, Delta-47, and HL60 cell lines were grown in 
IMDM (Hyclone) supplemented with 10 or 20  % Tet-
approved-FBS. HEK293T/17 cell line was grown in 
DMEM (Hyclone) supplemented with 10 % FBS. Trans-
fection was done according to manufacturer’s instruc-
tions using X-tremeGENE 9 DNA Transfection Reagent 
(Roche). To package lentivirus, HEK293T/17 cells were 
cotransfected with the vector Tet-pLKO-Neo (Addgene) 
or anti-BORIS shRNA derivatives and two packaged 
plasmids psPAX2 and Pmd2.G. Lentivirus stocks were 
collected 72 h post-transfection and used to infect K562 
at 40–50  % confluence using 500  µl lentivirus stock 
and 8  µg/ml polybrene (Sigma). The media were then 
changed 12 h after infection to include 600 µg/ml G418, 
and the cells were selected for G418 resistance for at least 
4  weeks. The resistant clones were selected in 96-well 
plates and analyzed by RT-qPCR and immunoblotting. 
The stable clones were induced by 200 ng/ml doxycycline 
to activate the Tet-On promoter.
The tiling repeat microarray
The design for this custom array [65] was conducted at 
Roche/Nimblegen using tiling approach. As a source for 
the design, we used a catalogue of human TRs generated 
by TR finder [110, 111]. The version of TRF algorithm 
used for the design of the array generated 947,696 dis-
tinct repeat instances based on the human genome. The 
tentative estimate of redundancy conducted by apply-
ing the most stringent versions of TRF suggests that the 
repeat dataset had about 40 % sequence redundancy. The 
repeats were broken into 50-base tiles using the following 
rules: Tiles were picked based on the predicted hybridi-
zation normalization; when the repeat was shorter than 
50 nucleotides, it was extended in tandem fashion. Our 
tiling approach has generated some additional redun-
dancy within tiles themselves because long homogeneous 
repeats produced a number of identical tiles. The redun-
dancies within the array did not interfere with microar-
ray data analysis, as the primary hybridization signal was 
recorded for each tile independently of any other. The 
final array design contained 2,166,672 features, including 
two control sets: 29,161 random sequence tiles and 181 
tiles from the rDNA locus of Saccharomyces cerevisiae.
ChIP‑chip and ChIP‑seq
For the ChIP-chip and ChIP-seq, anti-CTCF and anti-
BORIS ChIP were conducted from at least 50 million 
cells growing asynchronously. ChIP-seq preparation and 
analysis were done essentially as described in [55]. The 
specificity of ChIP reactions was validated by qPCR for 
known targets: the TSP50 and CST promoters for BORIS, 
and the MYC promoter sites for CTCF as in [96, 97].
For ChIP, cells growing asynchronously were cross-
linked (10  min, 1  % formaldehyde, 23  °C) quenched for 
10 min by 200 mM glycine, washed three times with PBS, 
and then resuspended in chromatin buffer (150 mM NaCl, 
1  % Triton X100, 0.1  % SDS, 20  mM Tris–HCl pH8.0, 
and 2 mM EDTA). DNA was sheared using Covaris S220, 
so that most fragments were in the 300- to 500-bp range. 
Chromatin was immunoprecipitated overnight with mag-
netic beads (DiaMag, Diagenode, Inc.) loaded with anti-
CTCF or anti-BORIS antibodies as described in [55]. The 
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immunoprecipitate was washed, cross-links reversed, pro-
tein component was digested with proteinase K, and DNA 
was extracted using phenol/chloroform/isoamyl alcohol. 
DNA concentration was measured by Qubit (Life Tech-
nologies) and/or Nanodrop (Thermo Scientific) fluorim-
eters. For ChIP-chip, the immunoprecipitated DNA was 
amplified using the Phi29 strand-displacement procedure 
(GE Bioscience) following the concatemerization of precip-
itated DNA fragments via ligation to double-strand adap-
tors containing BamHI overhangs and internal SapI sites. 
Both amplified and non-amplified samples showed essen-
tially the same relative enrichment for known sites of CTCF 
and BORIS binding. Following the amplification, adapters 
were removed by SapI digestion and agarose gel purifica-
tion. Input DNA was used as a hybridization reference for 
the hybridization of amplified ChIP DNA to a set of cus-
tom TR arrays (Roche-Nimblegen). Raw intensities for each 
channel were centered against the mean of control features 
set, including random oligonucleotides and yeast rDNA. 
Then, Lowess smoothing was applied to two-channel data 
to generate corrected M values that were used in subse-
quent analyses. The Lowess normalization, SAM, and PCA 
calculations were done using publicly available R scripts. 
For downstream analysis of ChIP-seq data, the Illumina 
reads (50  bp) were aligned to human repeat subgenome 
generated by TRF [111] using BLAT [112] (allowing 95 % 
identity) and/or Bowtie [113] (with parameters -v 2 --best 
--strata --tryhard). seqMINER [114] was used to analyze 
and plot CAGE expression data from published data-
sets. Motif Elicitation (MEME) software [115] was used 
to derive consensus sequences from genomic repeats with 
parameters (-mod oops -revcomp -w 20) to identify motifs 
on both DNA strands.
Analysis of public high‑throughput genomic data
ENCODE/RIKEN data (GSE34448) for K562 and NHEK 
cell lines were used in this study. The DSB maps of human 
meiosis were derived from [107].
Immunoblotting
Protein extracts were prepared by lysing cells SDS-PAGE 
sample buffer after washing with PBS supplemented with 
1× protease inhibitor cocktail (Roche Applied Science). 
Protein samples were separated by SDS-PAGE, trans-
ferred to a PVDF membrane, and incubated with the 
appropriate primary antibodies, followed by detection 
using LiCor secondary antibodies fused to fluorochromes. 
Photoluminescent images were captured by scanning and 
processed for quantification using LiCor workstation.
Immunofluorescent cell staining
K562 and HL60 cells were spun down in Cytospin cen-
trifuge (Thermo Scientific) onto poly-Lysine-coated 
coverslips and fixed with 4  % paraformaldehyde for 
10 min, followed by cold methanol for 10 min. Cells were 
permeabilized with 0.1  % Triton X-100/PBS for 10  min 
and then blocked with BSA for 30 min, after which they 
were incubated with primary antibodies. After washes, 
the anti-rabbit or anti-mouse secondary antibodies con-
jugated to either Alexa Fluor 647 or Alexa Fluor 488 were 
applied. Cells were mounted for microscopy in mount-
ing media containing DAPI and images captured using 
either confocal (Zeiss) or wide-field (Olympus) inverted 
microscopes.
Electrophoretic mobility shift assay (EMSA)
To map CTCF and BORIS binding sites in SVA repeats, 
the SVA subfamily D repeat (chr11: 107,782,495–
107,784,189, GRCh37/hg19) was covered with nine 
overlapping DNA probes either amplified by PCR or syn-
thesized as oligonucleotides (Additional file 3: Table S1). 
PCR amplified products were cloned into the pCR2.1 
TOPO vector (Invitrogen), and the sequence was con-
firmed by DNA sequencing. DNA fragments were 
labeled with [γ-32P] ATP at the 5′ ends by T4 polynu-
cleotide kinase per Invitrogen protocol. Labeled DNA 
fragments were gel purified, and equal amount of each 
fragment was used for EMSAs. FL human CTCF, 11ZF 
domain of CTCF, and FL human BORIS were synthesized 
from pCITE expression vectors (EMD Millipore), using 
the reticulocyte lysate-coupled in  vitro transcription-
translation system (TNT, Promega). Binding reactions 
for EMSA were for 1 h at 23 °C with 4 µl of in vitro syn-
thesized DNA-binding proteins in binding buffer [25 mM 
HEPES pH7.6, 100 mM KCl, 2 mM MgCl2, 10 % glycerol, 
0.5  µg poly(dIdC)  ×  poly(dIdC)]. DNA–protein com-
plexes were resolved on 5 % non-denaturing polyacryla-
mide gels in 0.5× Tris-borate-EDTA buffer. Gal3ST1 
promoter fragment was used in EMSA as a positive 
control for both CTCF and BORIS binding [97]. To test 
methylation sensitivity of protein binding, all labeled 
probes used in EMSA were methylated using SssI methyl-
transferase (New England BioLabs) by the following pro-
tocol: 200 ng of each oligonucleotide was combined with 
2.7  μl of NEBuffer 2, 3  μl (12  U) of SssI methylase and 
1 μl of S-adenosylmethionine (32 mM). After 3 h of incu-
bation at 37 °C, 0.5 μl of NEBuffer 2, 3 µl (12 U) of SssI 
methylase, and 1  μl of S-adenosylmethionine (32  mM) 
were added, and the reaction incubated for an additional 
3 h at 37 °C. The completion of methylation was assessed 
by digesting them with the methylation-sensitive enzyme 
AciI (Additional file 2: Figure S2B).
RT‑PCR and quantitative PCR
Total RNA was prepared using Trizol (Invitrogen). cDNA 
was prepared using the Primescript™ RT Reagent Kit 
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with genomic DNA Eraser (perfect real time) (TaKaRa) 
according to the manufacturer’s protocol. Quantitative 
PCR (qPCR) was performed using SYBR Premix Ex Taq™ 
(TaKaRa) and the Mx30005P QPCR System (Agilent).
RNA‑seq analysis
For the RNA-seq experiments, inducible BORIS knock 
down (KD) and control cell lines were created by infect-
ing K562 cells with 3 different Tet-on lentivirus constructs: 
empty vector pLKO-Tet-ON-neo [116], and two alterna-
tive anti-BORIS shRNA constructs. Several stable clones of 
each infected cell line were selected using 600 µg/ml G418. 
BORIS KD vectors were constructed to express the follow-
ing shRNA templates: GGAAATACCACGATGCAAATT 
(Site 1) and GGTGTGAAATGCTCCTCAACA (Site 2). 
For lentivirus vectors construction, the annealed oligonu-
cleotides were inserted into the pLKO-Tet-On-neo vec-
tor between AgeI and EcoRI restriction sites. After 72-h 
induction by doxycycline, BORIS mRNA was reproduc-
ibly showing 2.5-fold to threefold reduction, while BORIS 
protein levels were robustly decreased over fivefold (Fig. 6c, 
d). For RNA analysis, these K562-inducible stable shRNA 
cells were plated in 10-cm plates at 40–50 % confluence in 
DMEM media and left to grow in the presence of doxycy-
cline (200 ng/ml) for 96 h. For the 5-aza-deoxycytidine and 
DZNep experiments, cells were identically pretreated with 
doxycycline, harvested, and re-plated at 50–60  % conflu-
ence to grow 48 h in the presence of either 500 nM 5-aza-
2′-deoxycytidine, 1  µM DZNep or DMSO. The degree of 
genomic DNA demethylation was assessed using DNA IP 
with anti-5-methylcytosine mAb MABE146, clone 33D3 
(EMD Millipore), and qPCR against known targets. The 
effectiveness of DZNep treatment was assessed by immu-
noblotting against the EZH2 protein with D2C9 rabbit 
mAb (Cell Signaling Technology). The cells were then col-
lected, frozen, and outsourced for Illumina sequencing to 
RiboBio (Guangzhou). The amount of RNA submitted for 
each individual run was on average 85 µg (Nanodrop). The 
quality of RNA was assessed by the Agilent 2200 TapeSta-
tion. About 20 million reads were obtained for each individ-
ual experiment. Four biological replicates were produced 
and analyzed for each set of experimental conditions. The 
results of all RNA-seq experiments were analyzed for con-
sistency and reproducibility using Cufflinks 2.0.0 [117] fol-
lowing reads alignment to the human reference genome 
(hg38) using TopHat2, with the default parameter set-
ting. Upon that validation, for SVA alignment to RNA-seq 
data, a sub-genome file of 2223 SVA elements was assem-
bled from elements mapped in hg38 that were longer than 
1  kb, i.e., to ensure that VNTRs were included. The SVA 
elements were aligned to RNA-seq reads with Bowtie 
(-v0), and read counts per each element were normalized 
according to total read numbers in each experiment. Then, 
fold-enrichment ratios relative to the averaged normalized 
reads in the empty vector experiments were calculated.
Additional files
Additional file 1: Table S2. Classes of repeats co-occupied or differen-
tially occupied by CTCF and BORIS.
Additional file 2: Figure S2. BORIS binds at the same regulatory site as 
CTCF in rDNA. (A) The distribution of Chip-seq tags across the consensus 
rDNA repeat is shown for the input, CTCF ChIP-seq and BORIS ChIP-seq. 
The sites chosen for EMSA are indicated with brackets. (B) The correspond-
ing structure of “canonical” rDNA repeat. The long arrow corresponds 
to the Pol I transcript; the short arrow—noncoding RNA; NTS—non-
transcribed spacers. (C) EMSA of the chosen rDNA sites confirming that 
the known CTCF site in PolI promoter is co-occupied by CTCF in BORIS, 
while sampling of BORIS-only putative sites shows that there is no BORIS 
binding to these sites in vitro. (D) The assessment of CpG methylation for 
probe #3 used in (C) using the diagnostic digestion with Aci I endonucle-
ase, before and after methylation.
Additional file 3: Table S1. EMSA oligonucleotides.
Additional file 4: Figure S1. Extended analyses of SVA-D. (A) BORIS 
binding peaks at SVA VNTRs in Delta-47 cells. The ChIP-seq tag density 
distribution for the full-length SVA-D element from Repbase indicates that 
BORIS retains preference for VNTR region event in this cell line completely 
unrelated to K562 and with a substantially lower BORIS expression level. 
The normalized counts were binned along the DNA sequence (histo-
gram bars) with the smoothing line added. (B) The assessment if CpG 
methylation of oligonucleotides used in EMSA. DNA fragments were 
digested by the methylation-sensitive endonuclease Aci I before and after 
methylation.
Additional file 5: Figure S3. The expression of SVA elements that are 
transcribed in K562 cells is not affected by BORIS dosage. RNA-seq dif-
ferential ratio distribution for 75 SVA elements, which were apparently 
transcriptionally active in the untreated K562 cells (i.e., over 10 normalized 
counts in empty vector control). Only elements longer than 1 Kb were 
included in analysis. Shown are the graphs for BORIS KD K562 cells, K562 
treated with DZNep and the combination of both treatments.
Additional file 6: Figure S4. SVA elements capture BORIS binding sites 
from unique gene promoters. (A) BORIS ChIP-seq and deep CAGE (Cap 
Analysis of Gene Expression)-seq (ENCODE data) coverage tracks for the 
MAST2 gene (upper track) and for the SVA-F1 element (lower track) in K562 
cells. BORIS occupancy at the MAST2 first exon sequence coincided with 
the multiple transcription start sites (TSS) for MAST2 and SVA-F1 family 
expression in K562 cells. The black arrows show the direction of transcrip-
tion based on CAGEs enrichment on plus strand. The red double-headed 
arrows show the MAST2 sequence captured by SVA-F1 family from the 
MAST2 gene. (B) ChIP-seq enrichment of BORIS occupancy depends on 
the number of BORIS binding sites in the transduced sequences. The top 
panel is the schematic representation of SVA-F1 elements with different 
numbers of BORIS binding sites depending on the length of 5’-transduced 
sequence. The bottom panel is the plot showing the average tag density 
of BORIS ChIP-Seq across the transduced sequences of different length.
Additional file 7: Figure S5. Examples of BORIS binding at promoters 
trapped by SVA elements. The gene tracks represent cases of BORIS bind-
ing sites within genes’ promoters trapped by the indicated SVA element. 
The red double-headed arrows show the sequences trapped by SVAs 
and occupied by BORIS in K562 cells. BORIS ChIP-seq coverage and the 
CAGE tracks are shown for K562 cells. Expression from either minus or plus 
strands is shown by blue and red CAGE tracks, respectively. The particular 
examples are: BORIS binding site as the part of FDX1 promoter trapped 
by SVA-D, RHOT1 trapped by SVA-A, NDUFV2—by SVA-D, WRD33—SVA-F, 
PHKA1 and MMPE1—by SVA-D.
Additional file 8: Table S3. BORIS binding sites in the promoters of 
unique genes captured by SVA elements.
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